IND submission for intranasal SPC-15 treatment expected in 2025; Phase 1 clinical trial to follow upon approvalSP-26 ketamine implants nearing…
Study did not demonstrate statistically significant improvement on primary endpoint of reduction in depressive symptoms as measured by MADRS total…
TORONTO, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence…
LAS VEGAS, Dec. 30, 2024 /PRNewswire/ -- Assisted Intelligence Wellness Inc. (AI Wellness), a global leader in integrating AI with personalized…
Company Shifts Focus to Preparing for Commercial Launch as it Enters 2025BRAINTREE, Mass., Dec. 30, 2024 (GLOBE NEWSWIRE) -- Microbot…
RAD to advance the clinical development of Lantheus innovative radiopharmaceuticals in Australia Initial collaboration will focus on a Phase 1…
Proposed merger would add a differentiated Phase 3 TROP2 Antibody-drug Conjugate (ADC) to the combined company’s pipelinePALO ALTO, Calif., Dec.…
MIAMI, Dec. 27, 2024 /PRNewswire/ -- Navigantis Inc. announced today the first successful neurovascular clinical cases performed with its VASCO interventional…
Medical Co-working space challenges broken healthcare system. HOUSTON, TEXAS / ACCESSWIRE / December 23, 2024 / Honeycomb Clinic, the innovative…
MIAMI, FL / ACCESSWIRE / December 23, 2024 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), or the "Company", an emerging leader in…